Clinical trials: Eczema/Atopic Dermatitis
Eczema, Psoriasis
A Clinical Investigation With Epaderm® Cream
This investigation is designed as a prospective, non-randomised, single arm clinical investigation. Data is collected from approximately 120 evaluable subjects, divided into three groups of approximately 40 subjects; infants…
- Conditions
- Eczema, Psoriasis, Dry Skin; Eczema
- Trial name
- PD-539878 (NCT03738163)
- Testing
- Epaderm Cream
- Where
- 2 sites in United Kingdom
- Volunteers
- 121 people
- Sponsor
- Molnlycke Health Care AB
Atopic Dermatitis
Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis
This study is a phase 3, randomized, double blind and vehicle study to evaluate the efficacy and safety of Crisaborole ointment, 2% in Chinese and Japanese subjects with mild to moderate atopic dermatitis involving at least 5%…
- Trial name
- NCT04360187
- Testing
- Crisaborole Ointment
- Where
- 39 sites in China, Japan and 1 more
- Volunteers
- 391 people
- Sponsor
- Pfizer
Hand Eczema
Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- TRuE-CHE1 (NCT05219864)
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 49 sites in United States, Canada and 4 more
- Sponsor
- Incyte Corporation
Atopic Dermatitis
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
The purpose of this trial is to test different doses of the trial medicine (LEO 138559) and see how well they work and how safe they are at treating moderate to severe atopic dermatitis in adults.
- Trial name
- NCT05923099
- Testing
- LEO 138559
- Where
- 73 sites in United States, Canada and 9 more
- Volunteers
- 262 people
- Sponsor
- LEO Pharma
Dermatitis, Eczematous
Clinical Evaluation of Metal Panel Allergens: Dose Response Study
48-hour application of metal allergen patches to test for potential allergic responses.
- Trial name
- NCT02615249
- Testing
- Metal Allergen Epicutaneous Patch
- Where
- 8 sites in United States, Germany and 4 more
- Volunteers
- 122 people
- Sponsor
- Allerderm
Atopic Dermatitis
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
This is a Phase 3 Double Blind multi-center study conducted at 40 investigational sites in United States to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic…
- Trial name
- NCT05608343
- Testing
- Difamilast
- Where
- 39 sites in United States
- Volunteers
- 153 people
- Sponsor
- Acrotech Biopharma Inc.
Atopic Dermatitis, Atopic
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, AD
- Trial name
- NCT07011706
- Testing
- ATI-045
- Where
- 60 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
The primary objectives of this study are to: estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus response at Week 24 estimate vaccine response in rocatinlimab group vs placebo…
- Trial name
- ROCKET-VOYAGER (NCT05899816)
- Testing
- Rocatinlimab
- Where
- 85 sites in United States, Canada
- Volunteers
- 221 people
- Sponsor
- Amgen
Atopic Eczema
A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema
The primary objective of this study is to investigate the effect of AERODERM (also known as pitrakinra, AER 001, BAY 16-9996) on Eczema Area and Severity Index (EASI) score in subjects with moderate to severe atopic eczema
- Trial name
- NCT00676884
- Testing
- Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Aerovance, Inc.
Atopic Dermatitis
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the effect of nemolizumab (CD14152) on the pharmacokinetics (PK) of a drug "cocktail" representative of CYP450 (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5 sensitive index substrates) in…
- Trial name
- NCT04562116
- Testing
- Nemolizumab, CYP 450 Substrates
- Where
- 6 sites in United States, Bulgaria
- Volunteers
- 17 people
- Sponsor
- Galderma R&D
Dermatitis, Atopic
Protopic Ointment in Children Atopic Eczema
Children with atopic eczema and a poor response to topical corticosteroid applied either Protopic or Fluticasone ointment twice a day for 3 weeks. They could continue during 3 more weeks once a day if needed.
- Trial name
- NCT00689832
- Testing
- Tacrolimus 0.03%, Fluticasone 0.005%
- Where
- France
- Volunteers
- 487 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis
This is a phase II, double blind study with ZEP-3NA 0.1% or 1% vs. vehicle-control in subjects with mild to moderate Atopic Dermatitis.
- Trial name
- NCT04307862
- Testing
- ZEP-3Na 0.1%, ZEP-3Na 1%
- Where
- 10 sites in Israel
- Volunteers
- 165 people
- Sponsor
- Shulov Innovate for Science Ltd. 2012
Atopic Dermatitis
The Effect of Nature-based Exposure on the Immune System and Skin Health of Atopic Dermatitis Patients.
The purpose of the study is to explore the effect of nature-based exposure on immunological biomarkers and the condition and symptoms of atopic skin.
- Trial name
- NCT06129136
- Testing
- Nature-based exposure by biodiversity component in lotion.
- Where
- Finland
- Volunteers
- 142 people
- Sponsor
- Uute Scientific Oy
Atopic Dermatitis
Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis
This is a phase 1, single-center, first-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of DS-2741a after subcutaneous injection in healthy Japanese male volunteers and Japanese participants with…
- Trial name
- NCT04211415
- Testing
- DS-2741a
- Where
- Japan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Dermatitis Atopic
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
This is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss…
- Trial name
- PELISTAD-EX2 (NCT05983068)
- Testing
- dupilumab
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Sanofi
Atopic Dermatitis
Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj
A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results from the K0104 Extension Study
- Trial name
- NCT04730024
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 102 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Dermatitis, Atopic, Eczema, Atopic
Long-term Safety of Protopic in Atopic Eczema
Patients who have participated in previous studies with Tacrolimus ointment for atopic eczema are entitled to enter this four-year follow study to investigate the safety of treatment with Tacrolimus ointment 0.1%
- Trial name
- NCT00560378
- Testing
- Tacrolimus ointment 0.1%
- Where
- 41 sites in Belgium, Denmark and 10 more
- Volunteers
- 789 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis
The purpose of study BMX-05-001 is to evaluate the safety, tolerability, efficacy, and pharmacodynamics of BX005-A compared to vehicle administered topically in adult subjects with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT05240300
- Testing
- BX005-A
- Sponsor
- BiomX, Inc.
Cosmetics; Eczema
Effect of an Emollient Cream Containing 0.5% Cannabidiol and 1% Hemp Oil in the Hydration and Erythema of the Skin
This research seeks to evaluate the short (i.e., after single application) and long-term (i.e., after periodic application) hydrating effect of a topical preparation containing CBD and hemp oil on the skin of the volar forearm as…
- Trial name
- Celosia (NCT04045314)
- Testing
- Topical moisturizer
- Where
- Colombia
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Avicanna Inc
Dermatitis, Atopic
A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier
Atopic dermatitis (AD) is among the most common chronic types of inflammatory skin disease and it is characterised by exacerbations or relapses over years.
- Trial name
- NCT03901144
- Testing
- 2% urea/20% glycerol cream, Miniderm® 20% cream, Diprobase® cream
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- ACO Hud Nordic AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.